Hyeong Su Kim

2.8k total citations · 1 hit paper
117 papers, 1.7k citations indexed

About

Hyeong Su Kim is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Hyeong Su Kim has authored 117 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Oncology, 57 papers in Pulmonary and Respiratory Medicine and 31 papers in Molecular Biology. Recurrent topics in Hyeong Su Kim's work include Lung Cancer Treatments and Mutations (27 papers), Colorectal Cancer Treatments and Studies (24 papers) and Gastric Cancer Management and Outcomes (22 papers). Hyeong Su Kim is often cited by papers focused on Lung Cancer Treatments and Mutations (27 papers), Colorectal Cancer Treatments and Studies (24 papers) and Gastric Cancer Management and Outcomes (22 papers). Hyeong Su Kim collaborates with scholars based in South Korea, United States and Nigeria. Hyeong Su Kim's co-authors include Jung Han Kim, Bum Jun Kim, Hyun Joo Jang, Dae Young Zang, Soung Hoon Chang, Kun Sei Lee, Boram Han, Jae Wook Choi, Dae Ro Choi and Sung‐Hwa Sohn and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and The Journal of Immunology.

In The Last Decade

Hyeong Su Kim

115 papers receiving 1.6k citations

Hit Papers

Revolutionizing oncology: the role of Artificial Intellig... 2025 2026 2025 5 10 15 20
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Revolutionizing oncology: the role of Artificial Intelligence (AI) as an antibody design, and optimization tools
    2025 21 citations Vivek Kumar Morya, Yeon-Ju Kim et al. Biomarker Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hyeong Su Kim South Korea 24 650 615 437 308 249 117 1.7k
Sang‐Hee Cho South Korea 25 639 1.0× 496 0.8× 470 1.1× 510 1.7× 182 0.7× 139 1.9k
Maomao Cao China 17 738 1.1× 527 0.9× 592 1.4× 289 0.9× 383 1.5× 52 1.9k
Xiuying Gu China 15 455 0.7× 353 0.6× 322 0.7× 237 0.8× 259 1.0× 20 1.3k
Şuayib Yalçın Türkiye 24 1.1k 1.7× 780 1.3× 365 0.8× 470 1.5× 332 1.3× 173 2.1k
Yizhou Jiang United States 22 1.0k 1.6× 392 0.6× 465 1.1× 262 0.9× 149 0.6× 93 1.9k
Alessio Cortellini Italy 22 1.1k 1.6× 426 0.7× 332 0.8× 158 0.5× 219 0.9× 130 1.7k
Sally Temraz Lebanon 27 888 1.4× 405 0.7× 776 1.8× 258 0.8× 462 1.9× 97 2.1k
Cindy L. O’Bryant United States 23 738 1.1× 471 0.8× 917 2.1× 126 0.4× 220 0.9× 68 2.1k
Begoña de las Heras Spain 11 608 0.9× 321 0.5× 318 0.7× 229 0.7× 149 0.6× 27 1.8k
Ulrich Bork Germany 26 1.1k 1.6× 309 0.5× 383 0.9× 390 1.3× 484 1.9× 63 1.9k

Countries citing papers authored by Hyeong Su Kim

Since Specialization
Citations

This map shows the geographic impact of Hyeong Su Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hyeong Su Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hyeong Su Kim more than expected).

Fields of papers citing papers by Hyeong Su Kim

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hyeong Su Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hyeong Su Kim. The network helps show where Hyeong Su Kim may publish in the future.

Co-authorship network of co-authors of Hyeong Su Kim

This figure shows the co-authorship network connecting the top 25 collaborators of Hyeong Su Kim. A scholar is included among the top collaborators of Hyeong Su Kim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hyeong Su Kim. Hyeong Su Kim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Morya, Vivek Kumar, et al.. (2025). Revolutionizing oncology: the role of Artificial Intelligence (AI) as an antibody design, and optimization tools. Biomarker Research. 13(1). 52–52. 21 indexed citations breakdown →
3.
Lee, Kyung Jun, et al.. (2025). CT83 Promotes Cancer Progression by Upregulation of PDL1 in Adenocarcinoma of the Cervix. International Journal of Molecular Sciences. 26(6). 2687–2687. 3 indexed citations
4.
Lee, Kyung Jun, Hyeong Su Kim, Youngmi Kim, et al.. (2023). miR-429 Suppresses Endometrial Cancer Progression and Drug Resistance via DDX53. Journal of Personalized Medicine. 13(9). 1302–1302. 5 indexed citations
5.
Sharma, Ashish Ranjan, et al.. (2023). Insights from molecular dynamics simulations of TRPV1 channel modulators in pain. Drug Discovery Today. 28(12). 103798–103798. 6 indexed citations
6.
Jeong, Soo, et al.. (2022). Meta-Analysis of Survival Effects of Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1). Medicina. 58(12). 1867–1867. 1 indexed citations
7.
Sohn, Sung‐Hwa, et al.. (2021). TRK inhibitors block NFKB and induce NRF2 in TRK fusion-positive colon cancer. Journal of Cancer. 12(21). 6356–6362. 6 indexed citations
8.
Yoo, Changhoon, Boram Han, Hyeong Su Kim, et al.. (2018). Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-line Treatment for Patients with Recurrent or Metastatic Biliary Tract Cancer. Cancer Research and Treatment. 50(4). 1324–1330. 21 indexed citations
9.
Kim, Bum Jun, et al.. (2017). Moderate to Severe Thrombocytopenia During Pregnancy: A Single Institutional Experience. Indian Journal of Hematology and Blood Transfusion. 33(4). 581–585. 9 indexed citations
10.
Kim, Jung Han, Bum Jun Kim, Hyun Joo Jang, & Hyeong Su Kim. (2017). Comparison of the RECIST and EORTC PET criteria in the tumor response assessment: a pooled analysis and review. Cancer Chemotherapy and Pharmacology. 80(4). 729–735. 9 indexed citations
11.
Park, Cheol Woo, et al.. (2016). Microhabitat Characteristics of the Korean Endemic Cobitid Species Iksookimia hugowolfeldi Inhabited at Geogeum Island and Jangheung-gun in Korea. Korean Journal of Ichthyology. 28(1). 35–40.
12.
Kim, Hyeong Su, et al.. (2015). Chemotherapy in Elderly Patients with Gastric Cancer. Journal of Cancer. 7(1). 88–94. 39 indexed citations
13.
Choi, Dae Ro, Sang Nam Yoon, Hyeong Su Kim, et al.. (2015). A phase II study of capecitabine and oral leucovorin as a third-line chemotherapy in patients with metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology. 75(3). 639–643. 2 indexed citations
14.
Kim, Ho Young, Ju Kim, Dae Ro Choi, et al.. (2014). The Clinical Utility of FDG PET-CT in Evaluation of Bone Marrow Involvement by Lymphoma. Cancer Research and Treatment. 47(3). 458–464. 4 indexed citations
15.
Eom, Sang‐Yong, Jae Jeong Yang, Sung Sup Park, et al.. (2013). Polycyclic aromatic hydrocarbon-induced oxidative stress, antioxidant capacity, and the risk of lung cancer: a pilot nested case-control study.. PubMed. 33(8). 3089–97. 32 indexed citations
16.
Han, Boram, Choong Kee Park, Jong Hyeok Kim, et al.. (2013). Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology. 72(4). 845–852. 12 indexed citations
17.
Kwon, Jung Hye, Jung Han Kim, Jung-Ae Lee, et al.. (2010). Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology. 66(5). 889–897. 5 indexed citations
18.
Kim, Hyeong Su, Gyeong‐Won Lee, Jung Han Kim, et al.. (2010). A phase II study of pemetrexed and carboplatin as a salvage therapy for platinum-pretreated patients with non-small cell lung cancer. Lung Cancer. 70(1). 71–76. 13 indexed citations
19.
Kim, Jung Han, Hyeong Su Kim, Jong Soo Choi, et al.. (2008). Bilateral subdural hemorrhage as a possible adverse event of gefitinib in a patient with non-small cell lung cancer. Lung Cancer. 64(1). 121–123. 2 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sang‐Hee Cho Breakdown of academic impact, for papers by Maomao Cao Breakdown of academic impact, for papers by Xiuying Gu Breakdown of academic impact, for papers by Şuayib Yalçın Breakdown of academic impact, for papers by Yizhou Jiang Breakdown of academic impact, for papers by Alessio Cortellini Breakdown of academic impact, for papers by Sally Temraz Breakdown of academic impact, for papers by Cindy L. O’Bryant Breakdown of academic impact, for papers by Begoña de las Heras Breakdown of academic impact, for papers by Ulrich Bork
Rankless by CCL
2026